DocSym
β
Searchsearch
Search
(B55.2) Mucocutaneous leishmaniasis
More details coming soon
9 324 in individuals diagnosis mucocutaneous leishmaniasis confirmed
2 524 deaths with diagnosis mucocutaneous leishmaniasis
27% mortality rate associated with the disease mucocutaneous leishmaniasis
Diagnosis mucocutaneous leishmaniasis is diagnosed Men are 7.70% more likely than Women
5 021
Men receive the diagnosis mucocutaneous leishmaniasis
1 926 (38.4 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
4 303
Women receive the diagnosis mucocutaneous leishmaniasis
598 (13.9 %)Died from this diagnosis.
Risk Group for the Disease mucocutaneous leishmaniasis - Men aged 0-5 and Women aged 75-79
In Men diagnosis is most often set at age 0-14, 20-34, 45-69, 75-89
Less common in men the disease occurs at Age 15-19, 35-44, 70-74, 90-95+Less common in women the disease occurs at Age 0-1, 5-14, 20-24, 30-39, 50-54, 70-74, 90-95+
In Women diagnosis is most often set at age 0-5, 15-19, 25-29, 40-49, 55-69, 75-89
Disease Features mucocutaneous leishmaniasis
Absence or low individual and public risk
Mucocutaneous leishmaniasis - what does this mean
Mucocutaneous leishmaniasis is a rare and serious form of leishmaniasis caused by the leishmania parasite and spread by the bite of the female phlebotomine sandfly. it affects the skin, mucous membranes, and organs, and can cause severe disfiguring lesions, permanent scarring, and even death if left untreated.
What happens during the disease - mucocutaneous leishmaniasis
Mucocutaneous leishmaniasis is a disease caused by the protozoan parasite leishmania, which is transmitted to humans by the bite of infected sand flies. once inside the body, the parasite can cause skin ulcers, mucosal lesions, and other symptoms. the infection can spread to the lymph nodes and other organs, leading to systemic symptoms such as fever, weight loss, and anemia. it is treated with drugs that target the parasite and reduce inflammation.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Physical examination
- Skin biopsy
- Blood tests
- Imaging studies
- Polymerase chain reaction (PCR) tests
- Culture tests
- Serology tests
- Urine tests
- Sputum tests
Treatment and Medical Assistance
Main goal of the treatment: To reduce the symptoms of Mucocutaneous leishmaniasis and prevent further spread of the disease.
- Administering antileishmanial medications
- Performing surgery to remove lesions
- Providing wound care and topical treatments
- Administering supportive treatments such as antibiotics and antifungals
- Providing nutritional support to maintain the patient's health
- Providing psychological support to help manage stress and anxiety
- Educating the patient and family about the disease and the importance of following the treatment plan
21 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Mucocutaneous leishmaniasis - Prevention
Mucocutaneous leishmaniasis can be prevented by avoiding exposure to sandflies, using insect repellent, and wearing protective clothing when outdoors. vaccines are also available in some areas to help prevent the disease.